Neurocrine Retained Earnings vs Property Plant And Equipment Net Analysis

NBIX Stock  USD 127.11  1.46  1.16%   
Neurocrine Biosciences financial indicator trend analysis is infinitely more than just investigating Neurocrine Biosciences recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Neurocrine Biosciences is a good investment. Please check the relationship between Neurocrine Biosciences Retained Earnings and its Property Plant And Equipment Net accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Neurocrine Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.
For more information on how to buy Neurocrine Stock please use our How to Invest in Neurocrine Biosciences guide.

Retained Earnings vs Property Plant And Equipment Net

Retained Earnings vs Property Plant And Equipment Net Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Neurocrine Biosciences Retained Earnings account and Property Plant And Equipment Net. At this time, the significance of the direction appears to have fragmental relationship.
The correlation between Neurocrine Biosciences' Retained Earnings and Property Plant And Equipment Net is 0.57. Overlapping area represents the amount of variation of Retained Earnings that can explain the historical movement of Property Plant And Equipment Net in the same time period over historical financial statements of Neurocrine Biosciences, assuming nothing else is changed. The correlation between historical values of Neurocrine Biosciences' Retained Earnings and Property Plant And Equipment Net is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Retained Earnings of Neurocrine Biosciences are associated (or correlated) with its Property Plant And Equipment Net. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Property Plant And Equipment Net has no effect on the direction of Retained Earnings i.e., Neurocrine Biosciences' Retained Earnings and Property Plant And Equipment Net go up and down completely randomly.

Correlation Coefficient

0.57
Relationship DirectionPositive 
Relationship StrengthWeak

Retained Earnings

The cumulative amount of net income that a company retains for reinvestment in its operations, rather than distributing it to shareholders as dividends.

Property Plant And Equipment Net

The total value of a company's physical assets (such as land, buildings, and equipment) used in operations, net of depreciation. It reflects the company's investment in assets used for production.
Most indicators from Neurocrine Biosciences' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Neurocrine Biosciences current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Neurocrine Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.
For more information on how to buy Neurocrine Stock please use our How to Invest in Neurocrine Biosciences guide.At this time, Neurocrine Biosciences' Selling General Administrative is fairly stable compared to the past year. Tax Provision is likely to rise to about 63.8 M in 2024, whereas Issuance Of Capital Stock is likely to drop slightly above 22.9 M in 2024.

Neurocrine Biosciences fundamental ratios Correlations

0.190.960.90.990.970.390.470.980.460.990.860.950.970.450.680.630.90.960.940.990.570.870.930.210.79
0.190.170.350.110.20.39-0.570.210.080.160.020.310.10.590.190.390.460.340.180.220.60.090.30.210.03
0.960.170.940.970.940.380.560.970.390.950.830.890.980.370.50.630.820.890.920.950.640.880.880.140.78
0.90.350.940.880.910.580.420.950.230.880.810.860.920.370.410.80.80.890.890.910.850.740.890.230.6
0.990.110.970.880.960.320.540.980.430.980.880.920.990.410.620.550.880.910.940.970.520.870.90.210.8
0.970.20.940.910.960.370.570.990.340.980.910.860.960.290.590.620.810.911.00.920.60.810.860.190.74
0.390.390.380.580.320.37-0.030.43-0.370.360.340.410.380.210.210.780.40.50.360.410.740.130.410.38-0.18
0.47-0.570.560.420.540.57-0.030.540.010.530.610.230.58-0.450.020.180.060.30.580.390.080.480.27-0.110.44
0.980.210.970.950.980.990.430.540.340.980.90.90.980.340.560.670.840.930.980.950.650.840.90.210.73
0.460.080.390.230.430.34-0.370.010.340.420.10.550.330.520.660.090.50.490.280.49-0.020.630.49-0.270.84
0.990.160.950.880.980.980.360.530.980.420.860.90.960.370.670.580.860.940.970.950.530.860.860.160.78
0.860.020.830.810.880.910.340.610.90.10.860.740.920.150.390.460.690.750.930.820.490.630.760.430.55
0.950.310.890.860.920.860.410.230.90.550.90.740.90.630.730.660.960.950.830.980.610.830.980.260.76
0.970.10.980.920.990.960.380.580.980.330.960.920.90.350.520.590.840.890.950.960.590.830.90.270.74
0.450.590.370.370.410.290.21-0.450.340.520.370.150.630.350.510.240.740.50.250.520.320.390.570.310.39
0.680.190.50.410.620.590.210.020.560.660.670.390.730.520.510.40.720.780.560.680.160.640.630.070.63
0.630.390.630.80.550.620.780.180.670.090.580.460.660.590.240.40.550.750.60.660.90.440.710.10.29
0.90.460.820.80.880.810.40.060.840.50.860.690.960.840.740.720.550.910.780.930.570.750.910.310.69
0.960.340.890.890.910.910.50.30.930.490.940.750.950.890.50.780.750.910.890.960.660.830.920.20.73
0.940.180.920.890.941.00.360.580.980.280.970.930.830.950.250.560.60.780.890.90.580.770.830.220.7
0.990.220.950.910.970.920.410.390.950.490.950.820.980.960.520.680.660.930.960.90.610.860.970.260.78
0.570.60.640.850.520.60.740.080.65-0.020.530.490.610.590.320.160.90.570.660.580.610.370.670.190.22
0.870.090.880.740.870.810.130.480.840.630.860.630.830.830.390.640.440.750.830.770.860.370.790.090.89
0.930.30.880.890.90.860.410.270.90.490.860.760.980.90.570.630.710.910.920.830.970.670.790.270.75
0.210.210.140.230.210.190.38-0.110.21-0.270.160.430.260.270.310.070.10.310.20.220.260.190.090.27-0.14
0.790.030.780.60.80.74-0.180.440.730.840.780.550.760.740.390.630.290.690.730.70.780.220.890.75-0.14
Click cells to compare fundamentals

Neurocrine Biosciences Account Relationship Matchups

Neurocrine Biosciences fundamental ratios Accounts

201920202021202220232024 (projected)
Total Assets1.3B1.7B2.1B2.4B3.3B3.4B
Short Long Term Debt Total817.6M412.3M440.4M262.9M428.4M449.8M
Other Current Liab156.5M147.1M194.3M292M319.4M335.4M
Total Current Liabilities565.3M186.5M245.8M537.7M654.8M687.5M
Total Stockholder Equity636.9M1.1B1.4B1.7B2.2B2.3B
Property Plant And Equipment Net116.2M127.4M155.8M145.6M347.3M364.7M
Net Debt383.2M(388.7M)99.6M169.4M177.3M186.2M
Retained Earnings(1.1B)(725.4M)(635.8M)(406.8M)(157.1M)(165.0M)
Accounts Payable46.2M39.4M51.5M67.3M108.9M114.3M
Cash112.3M801M340.8M262.9M251.1M131.9M
Non Current Assets Total475M718.5M1.1B915.2M1.6B1.7B
Non Currrent Assets Other3.2M6.4M4.4M25M49.6M52.1M
Cash And Short Term Investments670.5M801M711.3M989.3M1.0B1.1B
Net Receivables126.6M157.1M185.5M350M439.3M461.3M
Common Stock Shares Outstanding95.7M97.8M97.9M98.9M101M61.8M
Liabilities And Stockholders Equity1.3B1.7B2.1B2.4B3.3B3.4B
Non Current Liabilities Total103.8M422M452.7M123.2M364.6M382.8M
Other Current Assets160.5M30.1M45.5M79.1M97.8M102.7M
Other Stockholder Equity1.8B1.8B2.0B2.1B2.4B2.5B
Total Liab669.1M608.5M698.5M660.9M1.0B1.1B
Property Plant And Equipment Gross116.3M127.4M155.8M145.6M430.3M451.8M
Total Current Assets831M1.0B972.8M1.5B1.6B1.7B
Accumulated Other Comprehensive Income1.4M1.8M(1.7M)(7.9M)7M7.4M
Short Term Debt408.8M10.3M16.5M169.4M202.1M212.2M
Short Term Investments558.2M613.9M370.5M726.4M780.5M819.5M
Other Liab17.1M9.7M12.3M29.7M34.2M24.8M
Other Assets59.1M674M319.5M330.9M380.5M399.6M
Long Term Debt388.5M408.8M317.9M335.1M385.4M404.6M
Common Stock Total Equity89K91K92K100K115K67.8K
Common Stock89K91K92K100K115K69.6K
Property Plant Equipment33.9M41.9M44.6M58.6M52.7M55.4M
Current Deferred Revenue(46.2M)(10.3M)(16.5M)229.3M263.7M276.9M
Net Tangible Assets228.1M1.1B1.4B1.7B1.9B2.0B
Retained Earnings Total Equity(1.1B)(725.4M)(635.8M)(406.8M)(366.1M)(384.4M)
Capital Surpluse1.8B1.8B2.0B2.1B2.4B1.6B
Inventory17.3M28M30.5M35.1M38.3M40.2M
Non Current Liabilities Other103.8M104.1M117.6M29.7M10.3M9.8M
Long Term Investments299.7M227.1M560.7M401.5M849.4M891.9M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Neurocrine Stock Analysis

When running Neurocrine Biosciences' price analysis, check to measure Neurocrine Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Neurocrine Biosciences is operating at the current time. Most of Neurocrine Biosciences' value examination focuses on studying past and present price action to predict the probability of Neurocrine Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Neurocrine Biosciences' price. Additionally, you may evaluate how the addition of Neurocrine Biosciences to your portfolios can decrease your overall portfolio volatility.